Despite Regulatory Setback, Spectrum Still “Unique Investment Opportunity,” Says Analyst – Spectrum Pharmaceuticals (NASDAQ:SPPI)
[ad_1] Yesterday, the FDA’s Oncologic Drugs Advisory Committee (ODAC) panel voted against Spectrum Pharmaceuticals Inc’s SPPI poziotinib’s (pozi) risk/benefit ratio and concluded that pozi’s benefits do not outweigh the risks for the…